Top Health-care stocks:
Health care shares were mostly unchanged in pre-market trade Tuesday.
In health care stocks news, Sucampo Pharmaceuticals ( SCMP ) reported that its drug candidate cobiprostone did not meaningfully improve heartburn symptoms in a Phase 2a study. Cobiprostone was being investigated for patients with non-erosive reflux disease (NERD), a subtype of gastro-esophagael reflux disease (GERD). The company said that because the trial did not meet its primary endpoints, it will discontinue development of cobiprostone for PPI-refractory NERD/sGERD.
SCMP shares were down 1.9% at $11.11 in pre-market trading , with a 52-week range of $9.59 - $29.67.
Johnson & Johnson ( JNJ ) reported Q1 adjusted earnings rose to $1.68 per diluted share from $1.56 a year ago, exceeding the $1.65 average estimate from analysts polled by Capital IQ. Revenue rose to $17.48 billion from $17.37 billion and was about in line with the $17.49 billion consensus estimate.
For 2016, Johnson & Johnson it expects sales between $71.2 billion and $71.9 billion reflecting current foreign currency exchange rates. The company previously predicted sales between $70.8 billion and $71.5 billion. Additionally, the company increased its adjusted earnings guidance for full-year 2016 to $6.53 - $6.68 per share, up from previously $6.43 to $6.58. The Street consensus is $71.5 billion in sales and earnings of $6.53 per share.
JNJ shares were up 0.7% at $111.67, on track to exceed its 52-week high of $111.10.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.